Experienced in Pulmonary Fibrosis

Dr. Udo Rudloff

Surgical Oncology
Center For Cancer Research Ccr Nci Nih, Hatfield Center, Room 4-5940, 10 Center Drive, 
Bethesda, MD 
Experienced in Pulmonary Fibrosis
Center For Cancer Research Ccr Nci Nih, Hatfield Center, Room 4-5940, 10 Center Drive, 
Bethesda, MD 
OverviewInsuranceLocationsClinical Research

Overview

Udo Rudloff is a Surgical Oncologist in Bethesda, Maryland. Dr. Rudloff is rated as an Experienced provider by MediFind in the treatment of Pulmonary Fibrosis. His top areas of expertise are Pancreatic Cancer, Stomach Cancer, Pancreatic Ductal Adenocarcinoma, Colorectal Cancer, and Pancreaticoduodenectomy.

His clinical research consists of co-authoring 53 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 2 articles in the study of Pulmonary Fibrosis.

Specialties
Surgical Oncology
Licenses
Surgery in NM
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Locations

Center For Cancer Research Ccr Nci Nih, Hatfield Center, Room 4-5940, 10 Center Drive, Bethesda, MD 20892

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Phase II Study of Selumetinib (AZD6244) for the Treatment of Advanced Pancreas Cancer Harboring KRAS G12R Mutations
A Phase II Study of Selumetinib (AZD6244) for the Treatment of Advanced Pancreas Cancer Harboring KRAS G12R Mutations
Enrollment Status: Completed
Publish Date: February 09, 2021
Intervention Type: Drug, Other
Study Phase: Phase 2
Phase II Study of Metastatic Melanoma Using a Nonmyeloablative Lymphodepleting Regimen Followed by Melanoma-Reactive T-Cells Sensitized in Vitro With Peptide-Pulsed Drosophila Cells
Phase II Study of Metastatic Melanoma Using a Nonmyeloablative Lymphodepleting Regimen Followed by Melanoma-Reactive T-Cells Sensitized in Vitro With Peptide-Pulsed Drosophila Cells
Enrollment Status: Terminated
Publish Date: August 01, 2017
Intervention Type: Drug
Study Phase: Phase 2
View 1 Less Clinical Trial

53 Total Publications

Emerging therapeutics targeting tumor-associated macrophages for the treatment of solid organ cancers.
Emerging therapeutics targeting tumor-associated macrophages for the treatment of solid organ cancers.
Journal: Expert opinion on emerging drugs
Published: May 12, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Rudloff's expertise for a condition
ConditionClose
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile